General : Dr Falk Pharma, Renexxion Report Positive Phase 2b Naronapride Results

KUALA LUMPUR, May 5 (Bernama) -- Dr Falk Pharma GmbH (Dr Falk Pharma) and Renexxion Ireland Limited (Renexxion) announced a Phase 2b trial of naronapride met its primary endpoint in adults with gastroparesis, showing statistically significant improvements in symptom scores versus placebo.

Go to News Site